Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 2 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Small Cell Lung Carcinoma 1 Rectal Diseases 1 Pancreatic Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms by Site 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Gallbladder Neoplasms 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Colonic Diseases 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 92 Nivolumab 56 Ipilimumab 55 Cyclophosphamide 52 Vemurafenib 28 fludarabine 27 aldesleukin 25 Interleukin-2 25 fludarabine phosphate 21 trametinib 20 dabrafenib 17 Temozolomide 14 Biopsy 14 Cisplatin 13 spartalizumab 12 atezolizumab 12 Carboplatin 11 cobimetinib 10 Specimen Handling 10 Paclitaxel 10 Introns 10 CTLA-4 Antigen 10 poly ICLC 9 binimetinib 9 Radiotherapy 9 Radiosurgery 9 MART-1 Antigen 9 tremelimumab 8 incomplete Freund's adjuvant 8 Radiation 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Melanoma × guadecitabine × Clear all

NCT02608437 2015-11-18

NIBIT-M4

Italian Network for Tumor Biotherapy Foundation

Phase 1 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡